64 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
president, drug assessment and development, at Chiron Corporation. Dr. Jallal has served on the board of directors of Elevance Health, Inc. (formerly Anthem … our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
. Jallal was vice president, drug assessment and development, at Chiron Corporation. Dr. Jallal has served on the board of directors of Elevance Health … risk assessment and management is undertaken. The audit committee also reviews and receives regular briefings concerning information security
10-K
2023 FY
EX-10.14
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
Salary (the “Target Bonus”). The Annual Bonus will be based upon the assessment of the Board of Directors (the “Board”) of Immunocore Holdings Plc … Market Value (as defined in the Plan) of 200% of your then-current Base Salary. The Annual Equity Award will be based upon the assessment of the Board
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions … the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline
10-K
2023 FY
EX-10.12
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
(the “Target Bonus”). The Annual Bonus will be based upon the assessment of the Board (or a committee thereof) of Executive’s performance
10-K
EX-10.13
khxyxcrn e7
28 Feb 24
Annual report
7:33am
8-K
EX-4.1
2618hgf zxpfxhw26f
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
6-K
EX-99.2
ud5df0g
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
x4zx22xd
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
ro4v7r
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
9npnv0 u0
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
0pmnyx11
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
gw1a nmey2ig7v
10 May 23
Current report (foreign)
7:27am
6-K
if1 vd3c4t
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
3jxryrq0y9kxch4
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K/A
EX-99.1
njiz0utkkrn xycq5v
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.1
cjv dp2snzktvabylo
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.4
tfrswnjwfqn 3lrd
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
yx1udp
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
flopkmupcxamp4tp
30 Sep 22
Prospectus with selling stockholder info
4:15pm